Galantamine in Treatment of AD
作者： M. Saleem Ismail , Pierre N. Tariot
DOI: 10.1007/978-1-59259-661-4_22
关键词:
摘要: The cholinergic hypothesis proposes that well-defined deficits in neurotransmission contribute to cognitive dysfunction Alzheimer’s disease (AD), and enhancing transmission will lead improved outcome (1). Several acetylcholinesterase inhibitors (AChEI) have been approved during the past few years on basis of clinical trials, demonstrating these agents improve or maintain function patients with possible AD. Thus far all AChEI shown be efficacious as a class are considered mainstay AD treatment. Galantamine is newest member this at present.
springer.com
sci-hub.st 参考文章(28)
A new rating scale for Alzheimer's disease. American Journal of Psychiatry. ,vol. 141, pp. 1356- 1364 ,(1984) , 10.1176/AJP.141.11.1356
Gordon K. Wilcock, Sean Lilienfeld, Galantamine alleviates caregiver burden in Alzheimer's disease: A 6-month placebo-controlled study Neurobiology of Aging. ,vol. 21, pp. 241- ,(2000) , 10.1016/S0197-4580(00)83423-5
Randolph W. Parks, Robert E. Becker, Robert F. Rippey, David G. Gilbert, Jane R. Matthews, Esperanza Kabatay, Carter S. Young, Cathy Vohs, Valerie Danz, Patricia Keim, G. Todd Collins, Steven S. Zigler, Paul G. Urycki, Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: A pilot double blind transdermal nicotine positron emission tomography study Neuropsychology Review. ,vol. 6, pp. 61- 79 ,(1996) , 10.1007/BF01875368
R. Bartus, R. Dean, B Beer, A. Lippa, The cholinergic hypothesis of geriatric memory dysfunction Science. ,vol. 217, pp. 408- 414 ,(1982) , 10.1126/SCIENCE.7046051
Edward D Levin, Amir H Rezvani, Development of nicotinic drug therapy for cognitive disorders. European Journal of Pharmacology. ,vol. 393, pp. 141- 146 ,(2000) , 10.1016/S0014-2999(99)00885-7
H. Feldman, A. Sauter, A. Donald, I. Gélinas, S. Gauthier, K. Torfs, W. Parys, A. Mehnert, The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Disease & Associated Disorders. ,vol. 15, pp. 89- 95 ,(2001) , 10.1097/00002093-200104000-00008
Handbook of dementing illnesses Alzheimer Disease & Associated Disorders. ,vol. 9, pp. 179- ,(1995) , 10.3109/9780849354847
Koen Torfs, Howard Feldman, 12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: Two randomized, placebo-controlled studies Neurobiology of Aging. ,vol. 21, pp. 242- 243 ,(2000) , 10.1016/S0197-4580(00)83429-6
OL Lopez, JT Becker, S Wisniewski, J Saxton, DI Kaufer, ST DeKosky, Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease Journal of Neurology, Neurosurgery & Psychiatry. ,vol. 72, pp. 310- 314 ,(2002) , 10.1136/JNNP.72.3.310
E.K. Perry, C.M. Morris, J.A. Court, A. Cheng, A.F. Fairbairn, I.G. McKeith, D. Irving, A. Brown, R.H. Perry, Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. ,vol. 64, pp. 385- 395 ,(1995) , 10.1016/0306-4522(94)00410-7